N-(4-bromophenyl)-6-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-bromophenyl)-6-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)pyrimidin-4-amine
• 英文别名: [4-[6-(4-Bromoanilino)pyrimidin-4-yl]phenyl]-[4-(2-fluorobenzoyl)piperazin-1-yl]methanone；[4-[6-(4-bromoanilino)pyrimidin-4-yl]phenyl]-[4-(2-fluorobenzoyl)piperazin-1-yl]methanone
• 化学式: C₂₈H₂₃BrFN₅O₂
• 分子量: 560.425
• InChiKey: BGSBJDMZBGVGEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-羧基苯硼酸 在 四(三苯基膦)钯 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 72.17h， 生成 N-(4-bromophenyl)-6-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)pyrimidin-4-amine
  参考文献：
  名称：

  Discovery of novel Bcr–Abl inhibitors targeting myristoyl pocket and ATP site

  摘要：

  Bcr-Abl plays an essential role in the pathogenesis and development of chronic myeloid leukaemia (CML). Inhibition of Bcr-Abl has great potential for therapeutic intervention in CML. In order to obtain novel and potent Bcr-Abl inhibitors, twenty seven 4,6-disubstituted pyrimidines were synthesized and evaluated herein. The biological results indicated that four compounds of them (C4, C5, C16, and C23) were potent Bcr-Abl inhibitors which were comparable to positive control. Moreover, C4 and C5 displayed promising antiproliferative activity against K562 cells. The results suggested that these 4, 6-disubstituted pyrimidines could serve as promising leads for further optimization of Bcr-Abl inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.10.030

文献信息

• Discovery of novel Bcr–Abl inhibitors targeting myristoyl pocket and ATP site
  作者：Jinyun Dong、Wen Lu、Xiaoyan Pan、Ping Su、Yaling Shi、Jinfeng Wang、Jie Zhang

  DOI：10.1016/j.bmc.2014.10.030

  日期：2014.12

  Bcr-Abl plays an essential role in the pathogenesis and development of chronic myeloid leukaemia (CML). Inhibition of Bcr-Abl has great potential for therapeutic intervention in CML. In order to obtain novel and potent Bcr-Abl inhibitors, twenty seven 4,6-disubstituted pyrimidines were synthesized and evaluated herein. The biological results indicated that four compounds of them (C4, C5, C16, and C23) were potent Bcr-Abl inhibitors which were comparable to positive control. Moreover, C4 and C5 displayed promising antiproliferative activity against K562 cells. The results suggested that these 4, 6-disubstituted pyrimidines could serve as promising leads for further optimization of Bcr-Abl inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.